Chinese (SSE) Biotech Industry Analysis

Industry Valuation and Performance

Has the Chinese Biotech Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 24 May 2026	CN¥841.0b	CN¥110.0b	-CN¥8,629,773,020.00	51.7x	-97.5x	7.6x
Tue, 21 Apr 2026	CN¥918.9b	CN¥109.9b	CN¥4.8b	46x	190.7x	8.4x
Thu, 19 Mar 2026	CN¥922.4b	CN¥110.2b	CN¥5.4b	43.5x	169.6x	8.4x
Sat, 14 Feb 2026	CN¥922.1b	CN¥106.5b	CN¥3.9b	47.6x	238.2x	8.7x
Mon, 12 Jan 2026	CN¥995.9b	CN¥106.1b	CN¥3.8b	48.8x	264x	9.4x
Wed, 10 Dec 2025	CN¥951.6b	CN¥106.1b	CN¥3.8b	48.7x	252.2x	9x
Fri, 07 Nov 2025	CN¥986.7b	CN¥106.1b	CN¥3.8b	49x	259.5x	9.3x
Sun, 05 Oct 2025	CN¥963.6b	CN¥107.5b	CN¥5.0b	49.2x	191.2x	9x
Tue, 02 Sep 2025	CN¥1.0t	CN¥108.3b	CN¥5.6b	45.6x	185.5x	9.6x
Thu, 31 Jul 2025	CN¥978.2b	CN¥112.9b	CN¥8.3b	42.7x	118.5x	8.7x
Sat, 28 Jun 2025	CN¥867.3b	CN¥112.9b	CN¥8.2b	38.7x	105.3x	7.7x
Mon, 26 May 2025	CN¥841.7b	CN¥113.1b	CN¥8.3b	34.9x	101.7x	7.4x
Wed, 23 Apr 2025	CN¥843.1b	CN¥134.3b	CN¥11.5b	38.8x	73.2x	6.3x
Fri, 21 Mar 2025	CN¥865.5b	CN¥136.2b	CN¥11.7b	32.4x	73.9x	6.4x
Sun, 16 Feb 2025	CN¥845.2b	CN¥136.0b	CN¥10.8b	34.2x	78.6x	6.2x
Tue, 14 Jan 2025	CN¥780.2b	CN¥135.2b	CN¥11.8b	31.1x	65.9x	5.8x
Thu, 12 Dec 2024	CN¥905.5b	CN¥136.0b	CN¥10.8b	34.5x	84.2x	6.7x
Sat, 09 Nov 2024	CN¥956.6b	CN¥141.7b	CN¥11.2b	38.4x	85.4x	6.7x
Mon, 07 Oct 2024	CN¥966.1b	CN¥154.1b	CN¥14.5b	39.2x	66.9x	6.3x
Wed, 04 Sep 2024	CN¥771.4b	CN¥154.0b	CN¥14.4b	30.3x	53.5x	5x
Fri, 02 Aug 2024	CN¥825.2b	CN¥161.2b	CN¥17.3b	31.3x	47.7x	5.1x
Sun, 30 Jun 2024	CN¥828.1b	CN¥161.1b	CN¥17.3b	31.6x	47.9x	5.1x
Tue, 28 May 2024	CN¥912.8b	CN¥161.1b	CN¥17.3b	37.6x	52.9x	5.7x
Thu, 25 Apr 2024	CN¥905.9b	CN¥163.7b	CN¥19.3b	35.7x	46.9x	5.5x
Sat, 23 Mar 2024	CN¥999.0b	CN¥165.5b	CN¥22.0b	37.7x	45.4x	6x
Mon, 19 Feb 2024	CN¥955.7b	CN¥167.9b	CN¥21.4b	31.9x	44.6x	5.7x
Wed, 17 Jan 2024	CN¥1.0t	CN¥167.9b	CN¥21.4b	37.8x	48.6x	6.2x
Fri, 15 Dec 2023	CN¥1.1t	CN¥168.1b	CN¥21.5b	39.6x	52.1x	6.7x
Sun, 12 Nov 2023	CN¥1.1t	CN¥168.1b	CN¥21.5b	41.3x	51.7x	6.6x
Tue, 10 Oct 2023	CN¥1.1t	CN¥170.9b	CN¥25.2b	42.9x	42.8x	6.3x
Thu, 07 Sep 2023	CN¥1.0t	CN¥170.7b	CN¥25.2b	38.2x	40.3x	5.9x
Sat, 05 Aug 2023	CN¥1.1t	CN¥174.4b	CN¥28.4b	39.3x	38.2x	6.2x
Mon, 03 Jul 2023	CN¥1.1t	CN¥177.4b	CN¥29.3b	40.1x	36.8x	6.1x
Wed, 31 May 2023	CN¥1.1t	CN¥177.4b	CN¥29.5b	43.1x	38.3x	6.4x

Current Industry PE

Investors are optimistic on the Chinese Biotechs industry, and appear confident in long term growth rates.

The 3-year average PS ratio of 6.9x is lower than the industry's current PS ratio of 7.6x.

Past Earnings Growth

Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
Revenues have also declined 15% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the Chinese Healthcare industry?


CN Market	-0.042%
Healthcare	-2.82%
Biotech	-3.84%
Biotech	-3.84%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
000518 Jiangsu Sihuan Bioengineering	CN¥4.13	27.9% +CN¥926.6m	98.6%	PS11.1x
688759 BeBetter Med	CN¥36.71	5.5% +CN¥855.1m	n/a	PB10.2x
688192 Dizal (Jiangsu) Pharmaceutical	CN¥54.56	2.3% +CN¥576.8m	-0.3%	PS28.4x
002030 Daan Gene	CN¥6.40	6.0% +CN¥505.2m	6.3%	PS12.2x
000403 Pacific Shuanglin Bio-pharmacy	CN¥11.51	2.8% +CN¥294.6m	-31.1%	PE31x

Company

Last Price

Valuation

000518 Jiangsu Sihuan Bioengineering

CN¥4.13

27.9%
+CN¥926.6m

98.6%

PS11.1x

688759 BeBetter Med

CN¥36.71

5.5%
+CN¥855.1m

n/a

PB10.2x

688192 Dizal (Jiangsu) Pharmaceutical

CN¥54.56

2.3%
+CN¥576.8m

-0.3%

PS28.4x

002030 Daan Gene

CN¥6.40

6.0%
+CN¥505.2m

6.3%

PS12.2x

000403 Pacific Shuanglin Bio-pharmacy

CN¥11.51

2.8%
+CN¥294.6m

-31.1%

PE31x

Sandoz Group AG Confirms European Commission Approval for Biosimilars Bysumlog® (Insulin Lispro) and Dazparda® (Insulin Aspart), Strengthening Position in Diabetes

Sandoz Group AG confirms that the European Commission has granted marketing authorisation for Bysumlog (insulin lispro) and Dazparda (insulin aspart). The two biosimilar insulins, for injection in prefilled pens, are developed by Gan & Lee Pharmaceuticals. Bysumlog is approved for the treatment and initial stabilisation of diabetes mellitus in adults and children1, while Dazparda is approved for the treatment of diabetes mellitus in adults, adolescents and children aged one year or more . Both biosimilar insulins have equivalent efficacy and comparable safety to their respective reference medicines, Humalog® and NovoRapid® . Following these approvals, Bysumlog and Dazparda have the potential to increase competition, improve affordability and expand access to insulin treatment options for millions of people living with diabetes across Europe. Diabetes is a chronic condition that occurs when either the pancreas does not produce enough insulin, a hormone that regulates blood glucose, or when the body cannot effectively use the insulin it produces. The disease and its complications can cause blindness, kidney failure, heart attacks, stroke and lower-limb amputation in some patients . An estimated 66 million adults aged 20–79 in Europe live with diabetes and this is projected to rise by 10% to 72 million by 2050, with related healthcare expenditure approaching USD 200 billion . Sandoz entered into an agreement with Gan & Lee in December 2018 to commercialise biosimilar versions of the insulins aspart, lispro and glargine. Under the terms of the agreement, Sandoz will commercialise in Europe and other key territories around the world, while Gan & Lee is responsible for development, manufacturing and supply. The approvals contribute to the continued Sandoz leadership and pioneering legacy in biosimilars, dating back to the introduction of the first biosimilar in 2006. They underscore the company’s commitment to help millions of patients access biologic medicines sustainably and affordably through a global portfolio of 13 biosimilars, supported by an industry-leading pipeline. They further strengthen the Sandoz position in diabetes, while representing another step towards the overall strategic objective of capitalising on a projected approximately USD 320 billion biosimilar market opportunity over the next 10 years .

Chinese (SSE) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Now 31% overvalued

Bio-Thera Solutions' Golimumab Biosimilars Receives FDA Approval as First Biosimilars to Simponi and Simponi Aria

Consensus EPS estimates fall by 26%

Sandoz Group AG Confirms European Commission Approval for Biosimilars Bysumlog® (Insulin Lispro) and Dazparda® (Insulin Aspart), Strengthening Position in Diabetes

Less than half of directors are independent

Now 20% overvalued

BeBetter Med Inc., Annual General Meeting, May 29, 2026

First quarter 2026 earnings released: EPS: CN¥0.048 (vs CN¥0.085 in 1Q 2025)

Full year 2025 earnings released: CN¥0.53 loss per share (vs CN¥0.66 loss in FY 2024)

First quarter 2026 earnings released: EPS: CN¥0.29 (vs CN¥0.17 in 1Q 2025)

First quarter 2026 earnings released: EPS: CN¥0.017 (vs CN¥0.016 loss in 1Q 2025)

First quarter 2026 earnings released: CN¥0.023 loss per share (vs CN¥0.13 loss in 1Q 2025)

First quarter 2026 earnings released: EPS: CN¥0.01 (vs CN¥0.005 in 1Q 2025)

Jinyu Bio-technology Co., Ltd., Annual General Meeting, May 18, 2026

Price target decreased by 19% to CN¥40.30

Full year 2025 earnings released: CN¥0.036 loss per share (vs CN¥0.11 loss in FY 2024)